SITC25: Findings Worth Your Attention
Welcome to SITC!
This year’s SITC delivered what the field desperately needs: less hype, more science, and a handful of presentations which should make several companies rather nervous about their clinical programmes.
From sensory neurons hijacking immune pathways to overhyped biomarkers built on just a few patients, this year’s meeting offered a masterclass in why mechanistic understanding matters more than gaudy clinical trial press releases.
What you’d find instead – if you knew where to look – was a conference rediscovering its scientific soul, complete with some genuinely uncomfortable findings to challenge current development strategies.
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
This is a two-part series this week where we go off the beaten track on the road less travelled to explore some novel approaches, which may or may not make an impact.
Fans of Harry Potter, will no doubt be familiar with the Goblet of Fire (“La Coupe de Feu” in the French version) and how it was used to select the champions from three schools of magic who would compete against each other in a tournament.
In other words, we need more firepower and novel rational combination approaches to stimulating both the innate and the adaptive immune systems in order to derive a more potent and durable response in a larger number of patients. That’s where TLR agonists come in.